Differential suppression of proliferation in MCF-7 and MDA-MB-231 breast cancer cells exposed to α-, γ- and δ-tocotrienols is accompanied by altered expression of oxidative stress modulatory enzymes

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4169-4176

  Hsieh, Tze Chen ^a   Elangovan, Selvakumar ^a   Wu, Joseph M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Breast cancer; Chemoprevention; MCF 7; MDA MB 231; NRF2; Tocotrienols

Indexed keywords

ALPHA TOCOTRIENOL; ANTINEOPLASTIC AGENT; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; DELTA TOCOTRIENOL; ESTROGEN RECEPTOR; GAMMA TOCOTRIENOL; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; SUPEROXIDE DISMUTASE; THIOREDOXIN; TOCOPHEROL; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CLONOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

BREAST NEOPLASMS; CATALASE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ENZYME INDUCTION; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RECEPTORS, ESTROGEN; SUPEROXIDE DISMUTASE; TOCOTRIENOLS;

EID: 78650231318     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Morrow M and Jordan VC: The current status of breast cancer chemoprevention: a star is born. J Surg Oncol 95: 4-5, 2007.
2. Jordan VC: A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 69: 1243-1254, 2009.
3. Phipps AI, Li CI, Kerlikowske K, Barlow WE and Buist DS: Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomarkers Prev 19: 1643-1654, 2010.
4. Zhao X, Li L and Wang Z: Chemoprevention of breast cancer: current status and future prospects. Front Biosci 11: 2249-2256, 2006.
5. Puntoni M and Decensi A: The rationale and potential of cancer chemoprevention with special emphasis on breast cancer. Eur J Cancer 45(Suppl 1): 346-354, 2009.
6. Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M and Steger G: Breast cancer chemoprevention - a vision not yet realized. Eur J Cancer Care (Engl) 18: 438-446, 2009.
7. Jeong WS, Jun M and Kong AN: NRF2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 8: 99-106, 2006.
8. Paluszczak J, Krajka-Kuzniak V and Baer-Dubowska W: The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett 192: 119-125, 2010.
9. Murthy NS, Mukherjee S, Ray G and Ray A: Dietary factors and cancer chemoprevention: an overview of obesity-related malignancies. J Postgrad Med 55: 45-54, 2009.
10. Packer L and Landvik S: Vitamin E: introduction to biochemistry and health benefits. Ann NY Acad Sci 570: 1-6, 1989.
11. Weber C, Podda M, Rallis M, Thiele JJ, Traber MG and Packer L: Efficacy of topically applied tocopherols and tocotrienols in protection of murine skin from oxidative damage induced by UV-irradiation. Free Radic Biol Med 22: 761-769, 1997.
12. Salobir J, Zontar TP, Levari A and Rezar V: The comparison of black currant juice and vitamin E for the prevention of oxidative stress. Int J Vitam Nutr Res 80: 5-11, 2010.
13. Cordera Z, Drogan D, Weikert C and Boeing H: Vitamin E and risk of cardiovascular diseases: a review of epidemiologic and clinical trial studies. Crit Rev Food Sei Nutr 50: 420-440, 2010.
14. Pazdro R and Burgess JR: The role of vitamin E and oxidative stress in diabetes complications. Mech Ageing Dev 131: 276-286, 2010.
15. Packer L, Weber SU and Rimbach G: Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling. J Nutr 131: 369S-373S, 2001.
16. Ju J, Picinich SC, Yang Z, Zhao Y, Suh N, Kong AN and Yang CS: Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis 31: 533-542, 2010.
17. Mizushina Y, Nakagawa K, Shibata A, Awata Y, Kuriyama I, Shimazaki N, Koiwai O, Uchiyama Y, Sakaguchi K, Miyazawa T and Yoshida H: Inhibitory effect of tocotrienol on eukaryotic DNA polymerase lambda and angiogenesis. Biochem Biophys Res Commun 339: 949-955, 2006.
18. Banks R, Speakman JR and Selman C: Vitamin E supplementation and mammalian lifespan. Mol Nutr Food Res 54: 719-725, 2010.
19. Galli F and Azzi A: Present trends in vitamin E research. Biofactors 36: 33-42, 2010.
20. Wells SR, Jennings MH, Rome C, Hadjivassiliou V, Papas KA and Alexander JS: Alpha-, gamma- and delta-tocopherols reduce inflammatory angiogenesis in human microvascular endothelial cells. J Nutr Biochem 21: 589-597, 2010.
21. Wada S: Chemoprevention of tocotrienols: the mechanism of antiproliferative effects. Forum Nutr 61: 204-216, 2009.
22. Stone WL, Krishnan K, Campbell SE, Qui M, Whaley SG and Yang H: Tocopherols and the treatment of colon cancer. Ann NY Acad Sci 1031: 223-233, 2004.
23. Nesaretnam K, Dorasamy S and Darbre PD: Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. Int J Food Sci Nutr 51 Suppl: S95-103, 2000.
24. Pierpaoli E, Viola V, Pilolli F, Piroddi M, Galli F and Provinciali M: Gamma- and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression. Life Sci 86: 668-675, 2010.
25. McIntyre BS, Briski KP, Gapor A and Sylvester PW: Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224: 292-301, 2000. (Pubitemid 30643508)
26. Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG and Kline K: Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer 48: 95-105, 2004.
27. Comitato R, Nesaretnam K, Leoni G, Ambra R, Canali R, Bolli A, Marino M and Virgili F: A novel mechanism of natural vitamin E tocotrienol activity: involvement of ERbeta signal transduction. Am J Physiol Endocrinol Metab 297: E427-437, 2009.
28. Sylvester PW, Russell M, Ip MM and Ip C: Comparative effects of different animal and vegetable fats fed before and during carcinogen administration on mammary tumorigenesis, sexual maturation, and endocrine function in rats. Cancer Res 46: 757-762, 1986.
29. Sundram K, Khor HT, Ong AS and Pathmanathan R: Effect of dietary palm oils on mammary carcinogenesis in female rats induced by 7,12-dimethylbenz(a) anthracene. Cancer Res 49: 1447-1451, 1989.
30. Nesaretnam K: Multitargeted therapy of cancer by tocotrienols. Cancer Lett 269: 388-395, 2008.
31. Sen CK, Khanna S and Roy S: Tocotrienols in health and disease: the other half of the natural vitamin E family. Mol Aspects Med 28: 692-728, 2007.
32. Nesaretnam K, Ambra R, Selvaduray KR, Radhakrishnan A, Reimann K, Razak G and Virgili F: Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice. Lipids 39: 459-467, 2004.
33. Comitato R, Leoni G, Canali R, Ambra R, Nesaretnam K and Virgili F: Tocotrienols activity in MCF-7 breast cancer cells: involvement of ERbeta signal transduction. Mol Nutr Food Res 54: 669-678, 2010.
34. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the Chinese herb Rabdosia albescens. Biochem Biophys Res Commun 337: 224-231, 2005.
35. Aebi H: Catalase in vitro. Methods Enzymol 105: 121-126, 1984.
36. Lind C, Cadenas E, Hochstein P and Ernster L: DT-diaphorase: purification, properties, and function. Methods Enzymol 186: 287-301, 1990.
37. Flohe L and Gunzler WA: Assays of glutathione peroxidase. Methods Enzymol 105: 114-121, 1984.
38. Shen G, Jeong WS, Hu R and Kong AN: Regulation of NRF2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents. Antioxid Redox Signal 7: 1648-1663, 2005.
39. Giudice A and Montella M: Activation of the NRF2-ARE signaling pathway: a promising strategy in cancer prevention. Bioessays 28: 169-181, 2006.
40. Kundu JK and Surh YJ: NRF2-KEAP1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis. Pharm Res 27: 999-1013, 2010.
41. Kensler TW and Wakabayashi N: NRF2: friend or foe for chemoprevention? Carcinogenesis 31: 90-99, 2010.
42. Kwak MK and Kensler TW: Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244: 66-76, 2010.
43. Jana S and Mandlekar S: Role of phase II drug metabolizing enzymes in cancer chemoprevention. Curr Drug Metab 10: 595-616, 2009.
44. Nesaretnam K, Stephen R, Dils R and Darbre P: Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 33: 461-469, 1998.
45. Veal EA, Day AM and Morgan BA: Hydrogen peroxide sensing and signaling. Mol Cell 26: 1-14, 2007.
46. Day AM and Veal EA: Hydrogen peroxide-sensitive cysteines in the Sty1 MAPK regulate the transcriptional response to oxidative stress. J Biol Chem 285: 7505-7516, 2010.
47. 2-scavenging and signaling. Antioxid Redox Signal 10: 1565-1576, 2008.